Achieve Life Sciences Inc Stock Price, News & Analysis

Achieve Life Sciences (Nasdaq: ACHV) reported Q3 2020 financial results, highlighting the initiation of the Phase 3 ORCA-2 trial for cytisinicline, aimed at smoking cessation. The trial involves 750 smokers and compares cytisinicline's efficacy against placebo. The company announced a cash position of $22.4 million with Q3 operating expenses of $3.8 million, leading to a net loss of $3.8 million. Cytisinicline showed promising results in a previous trial against Chantix, revealing fewer adverse events and higher quit rates. A virtual roundtable on smoking cessation is scheduled for November 17, 2020.

Achieve Life Sciences, Inc. (Nasdaq: ACHV) will release its third quarter 2020 financial results on November 12, 2020, at 4:30 PM ET. The company is focused on the development of cytisinicline for smoking cessation and nicotine addiction. The earnings call will provide updates on this program, and interested parties can access the call via their Investor Relations page or by phone. A replay will be available approximately two hours after the call.

Achieve Life Sciences (NASDAQ: ACHV) is hosting a virtual roundtable on November 17, 2020, at 12:00 PM EST to discuss cytisinicline's role in smoking cessation. The event features a principal investigator from the ongoing ORCA-2 Phase 3 trial and a review of results from the RAUORA study comparing cytisinicline to Chantix. Moderated by healthcare analysts, the discussion emphasizes the importance of smoking cessation during the COVID-19 pandemic. Esteemed experts from Harvard, Stanford, and other institutions will participate.

Achieve Life Sciences (NASDAQ: ACHV) announced its invitation to present at the MicroCap Rodeo Best Ideas Bowl, scheduled for October 13-16, 2020. CEO John Bencich will present on October 13 at 3:30 p.m. ET, with one-on-one meetings available throughout the event. The presentation will be webcast live at this link. Achieve is focused on developing cytisinicline, a plant-based solution for smoking cessation, which has helped over 20 million users in Europe.

Achieve Life Sciences (NASDAQ: ACHV) announced the initiation of the Phase 3 ORCA-2 clinical trial, evaluating the efficacy and safety of 3 mg cytisinicline for smoking cessation among 750 adult smokers at 15 U.S. clinical sites. The trial compares two treatment durations against placebo, measuring successful smoking cessation over the final four weeks. Achieve aims to improve quit rates based on previous ORCA-1 findings, with the potential for cytisinicline to be a well-tolerated treatment option if approved.

Achieve Life Sciences (Nasdaq: ACHV) has appointed John Bencich as the new Chief Executive Officer, transitioning from his previous role as Chief Financial and Operating Officer. Cindy Jacobs is promoted to President, while Anthony Clark will continue as Chief Scientific Officer after stepping down from the Board. The company has approximately $26.7 million in cash and plans to initiate the Phase 3 ORCA-2 trial in Q4 2020 for its smoking cessation drug, cytisinicline, which has been used by over 20 million people in Europe.

Achieve Life Sciences, Inc. (Nasdaq: ACHV) has announced positive results from the RAUORA trial, comparing cytisinicline to varenicline for smoking cessation among 679 Māori participants. The trial showed cytisinicline met the non-inferiority endpoint with a 4.29% higher quit rate (12.1% vs. 7.9%). Furthermore, cytisinicline demonstrated significantly fewer adverse events (AEs), particularly less nausea (22.5% vs. 39.1%). The trial's findings support the efficacy of cytisinicline and set the stage for the upcoming Phase 3 ORCA-2 trial.

Achieve Life Sciences (NASDAQ: ACHV) presented findings at the SRNT-E Annual Meeting on cytisinicline, a smoking cessation treatment. Research shows that cytisinicline has a significantly lower binding affinity at the 5-HT₃ receptor compared to varenicline, which may explain its reduced incidence of nausea and vomiting. Conducted by researchers at the University of Cambridge, the study underscores the importance of side effects on treatment compliance, potentially impacting smoking cessation success. Achieve continues to develop cytisinicline as an effective alternative for nicotine addiction.

Achieve Life Sciences, Inc. (NASDAQ: ACHV) announced that data on cytisinicline will be presented at the SRNT-E virtual conference on September 18. The presentations will compare cytisinicline to varenicline (Chantix®), highlighting its lower incidence of nausea and vomiting. Cytisinicline, a plant-based treatment approved in Central and Eastern Europe, has helped over 20 million users combat nicotine addiction. Achieve aims to address the global smoking epidemic with this drug, which interacts with nicotine receptors to ease withdrawal symptoms.